You are here: Home » European Pharmaceutical Review magazine » Past issues » Issue 4 2005
You must be a member to access this exclusive content!
Silver membership gives you:
- Exclusive access to every article from our back issue archive
- Our regular email newsletter
Or become a subscriber and also get:
- Six issues of European Pharmaceutical Review (printed magazine)
Join now >>
Issue 4 2005
Issue 4 2005 / 11 November 2005 / Oliver C. Steinbach, Head of Department, Technology Management, ALTANA Pharma AG
RNAi technology provides the ‘loss of function’ approach, which has been widely used in the last couple of years for analysis of gene function, and in drug discovery for identification and validation of potential drug target candidates. This technology is now widely applied for functional screens in order to identify disease associated signals and targets whose specific inhibition could potentially result in a curative effect for treatment of complex human diseases. The focus of such screens is evolving more towards druggable gene families rather than genome wide approaches – the latter being expensive, complex and sometimes confusing.
(more…)
Tagged with: Altana Pharma, Functional genomics, Oliver C. Steinbach
Issue 4 2005 / 11 November 2005 / EPR
The conclusion of the Genome Sequencing Project – far from providing the solution to the problem of human disease – has created further questions that had not previously been considered. Hence, the age of genomics has initiated the need to examine the body’s real biochemical actors: proteins, to learn about their role in human health and disease.
(more…)
Tagged with: Proteomics
Issue 4 2005 / 11 November 2005 / Gareth Elvidge, PhD, Genomics Group, Wellcome Trust Centre for Human Genetics, University of Oxford
The expansion of microarray-based gene expression studies has led to an increase in demand for gene-specific PCR-based methods for independent validation of results. Although a number of technologies are available to meet this requirement the most popular is currently real-time PCR.
(more…)
Tagged with: Gareth Elvidge, PCR, University of Oxford
Issue 4 2005 / 11 November 2005 / Martin J. Main, Karen Jones, Biological Chemistry, AstraZeneca R&D, UK, Mats A. Svensson, Dirk Weigelt and Markus Haeberlein, Chemistry, AstraZeneca R&D, Sweden
Advances in assay technology are driving an exciting new era in ion channel drug discovery. Here, we present a case study describing the use of computational chemistry and focussed library screening to drive rapid hit identification.
(more…)
Tagged with: AstraZeneca R&D, Dirk Weigelt, Ion Channel Drug Discovery, Karen Jones, Markus Haeberlein, Martin J. Main, Mats A. Svensson
Issue 4 2005 / 11 November 2005 / Dr Frank Straube, Biomarker Expert, Novartis Pharma AG
High content imaging (HCI), the combination of automated fluorescence microscopy with quantitative image analysis, has been opening new dimensions in cytometry. This article gives an overview on the growing spectrum of applications and an outlook on the future use of this still rapidly developing technology.
(more…)
Tagged with: Dr Frank Straube, HCS (High Content Screening), Novartis Pharma AG
Issue 4 2005 / 11 November 2005 / Steve Doherty and Aaron Garrett, Manufacturing Science and Technology, Mark LaPack, Process Research and Development, Eli Lilly and Co.
Optical techniques can not address every application need, so the well-equipped PAT toolbox must include a broad array of technologies. One analytical tool that has been less-published but no less useful than the optical methods is mass spectrometry. This article provides a brief review of some of the published uses of process mass spectrometry, and provides some specific examples from the authors’ labs that demonstrate the value and utility of this technique.
(more…)
Tagged with: Aaron Garrett, Eli Lilly and Co., Mark LaPack, PAT, Steve Doherty
Issue 4 2005 / 11 November 2005 / Royston Goodacre and Roger M. Jarvis, School of Chemistry, The University of Manchester
Raman spectroscopy is a highly versatile tool that provides chemical fingerprints from biological material that can be interpreted using chemometrics and machine learning. In combination this powerful approach is being developed for the quantitative determination of multiple determinands in bioprocesses and for the characterisation of microorganisms.
(more…)
Tagged with: Raman Spectroscopy, Roger M. Jarvis, Royston Goodacre, University of Manchester
Issue 4 2005 / 11 November 2005 / Dr Paul G. Royall, Lecturer in Pharmaceutics, School of Chemical Sciences & Pharmacy University of East Anglia, See-wah Jai Tang, Pharmaceutical Science Research Division, King’s College London
Thermal analysis equipment can be found in nearly all of the analytical, development, formulation and QA laboratories within the pharmaceutical industry. However, these work horse instruments are learning to run faster and to analyse an ever more varied field of samples.
(more…)
Tagged with: King’s College London, Paul G. Royall, See-wah Jai Tang, Thermal Analysis, University of East Anglia
Issue 4 2005 / 11 November 2005 / Michael Wiggenhorn, Gerhard Winter, Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-University and Ingo Presser, Boehringer Ingelheim
Freeze drying is a widely used method to stabilise protein pharmaceuticals. The stability of proteins and the biological activity can be influenced by several factors, which may lead to conformational changes and to denaturation, aggregation or absorption to surfaces1.
(more…)
Tagged with: Boehringer Ingelheim, Gerhard Winter, Ingo Presser, Ludwig-Maximilians-University, Lyophilization, Michael Wiggenhorn
Issue 4 2005 / 11 November 2005 / Amy McDaniel, Ph.D., QC Manager, Microbial Science & Technology, Wyeth Biotech
Timely results for microbial bioburden monitoring of in-process cell culture samples are critical to the production process for recombinant proteins and other biopharmaceutical products.
(more…)
Tagged with: Amy McDaniel, Microbiology, Wyeth Biotech
Login to access exclusive content